Navigation Links
In Vitro Safety Screening for Clinical Liabilities, New Life Science Webinar hosted by Xtalks
Date:8/23/2013

Toronto, Canada (PRWEB) August 23, 2013

In vitro pharmacological profiling, testing compounds in select panels of assays like SafetyScreen, play an increasingly important role in reducing drug related safety attrition. In vitro screening identifies off-target activities and their adverse reaction potential by testing compounds for their activity in pharmacologically relevant targets like Serotonin 5H2B, hERG, and others and allows for early risk assessment of compounds. Failure to identify the adverse drug potential of a lead compound may have devastating consequences in later stages of clinical development.

There are several advantages of in vitro profiling; it allows optimizing compounds for specificity and selectivity enables cost effective testing of multiple compounds in parallel, uses species relevant targets and provides fast turnaround times. In vitro screening, when coupled with Pharmaco-Informatics tools can provide valuable information related to potential adverse events, therapeutic applications, repurposing and in vivo efficacy.

Join Dr. Gonzallo Castillo, Technical Director at Eurofins Panlabs, for an informative session. A live Q&A session will follow the main presentation.

To learn more about the event, visit:
http://www.xtalks.com/anti-infective-services-for-drug-discovery.ashx.ashx

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/8/prweb11047853.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. In Vitro Diagnostics Market is Expected to Reach USD 74.2 Billion Globally in 2018: Transparency Market Research
2. Hurel Corporation Launches Cell-Based In Vitro Testing Product Suite, Milestone in Movement Away from Use of Live Animals in Drug and Toxicity Testing
3. Marken Meets Critical Demand For In Vitro Lab Shipments
4. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
5. In Vitro Diagnostics (IVD) - Emerging Countries (Brazil, Russia, India, China) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
6. Auxogyn And Reproductive Medicine Associates of New Jersey Partner To Advance in vitro fertilization Research
7. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
8. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
9. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
10. Pharmaceutical and Food Product Safety Made Easier with the Environmental Wireless Validation System by Deadline Solutions, Inc
11. Mucosis Announces Publication of Data Demonstrating Safety and Protection by Mucosally Administered Mimopath®-based Prefusion-like F RSV Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... King of Prussia, PA (PRWEB) , ... August 16, 2017 , ... ... leaders will be taking part in sessions at the ISPE Annual Meeting and ... the Marriott Marquis San Diego Marina. The event’s theme is “Driving innovation to advance ...
(Date:8/16/2017)... ... August 16, 2017 , ... Recent studies show ... Many treatments for specific cancers, such as breast, prostate, or lung, target vital ... deprivation therapy for advanced prostate cancer. , This therapy limits the production ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics Inc ... $2M in funding from an impressive group of investors, including Rev1 Ventures, Maumee ... With this investment, 3Bar is broadening availability of its groundbreaking offering that uses ...
(Date:8/16/2017)... of the Inc. 5000 features a now-familiar name: BioPoint ( http://biopointinc.com/ ), ... for the third year in a row. Now in its 36th edition, ... set of quantitative metrics. In addition, BioPoint was also named to the ... Bay State . ... ...
Breaking Biology Technology:
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):